Global Restless Legs Syndrome Market 2015-2019

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Product Profiles
05.1 Mirapex/Sifrol/Mirapexin
05.2 Requip
05.3 Neupro/Leganto
05.4 HORIZANT/Regnite
06. Introduction
07. Disease Overview
07.1 Understanding RLS
07.1.1 Types of RLS
07.2 Etiology and Pathogenesis
07.2.1 Genetic Factors
07.2.2 Iron Deficiency
07.2.3 Other Disease Conditions/Medications
07.2.4 Neurological Disturbances
07.3 Signs and Symptoms
07.4 Diagnosis
07.4.1 Differential Diagnosis of RLS
07.5 Management
07.5.1 Pharmacological Therapy
07.5.2 Non-pharmacological Therapy
07.6 Epidemiology
07.7 Economic Burden
08. Pipeline Analysis
08.1 Key Information on Pipeline Candidates
08.1.1 Injectafer
08.1.2 Lisuride
08.1.3 Incobotulinumtoxin A
08.1.4 IPX-159
08.1.5 Safinamide
08.1.6 AZ-008
08.1.7 SER-214
09. Commercial Opportunities
10. Key Brand Analysis
11. Market Landscape
11.1 Market Overview
11.2 Market Size and Forecast
11.3 Five Forces Analysis
12. Market Segmentation by Class of Drugs
12.1 Dopaminergic Drugs
12.2 Opioids
12.3 Anticonvulsants
12.4 Sedatives and Hypnotics
12.5 Others
13. Geographical Segmentation
13.1 Global Restless Legs Syndrome Market by Geography 2014-2019
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2014
21.2.1 UCB
21.2.2 GlaxoSmithKline
21.2.3 Boehringer Ingelheim
21.2.4 XenoPort
21.3 Other and Future Prominent Vendors
22. Key Vendor Analysis
22.1 Boehringer Ingelheim
22.1.1 Key Facts
22.1.2 Business Overview
22.1.3 Business Segmentation by Revenue 2013
22.1.4 Business Segmentation by Revenue 2012 and 2013
22.1.5 Geographical Segmentation by Revenue 2013
22.1.6 Business Strategy
22.1.7 Recent Developments
22.1.8 SWOT Analysis
22.2 GlaxoSmithKline
22.2.1 Key facts
22.2.2 Business overview
22.2.3 Business segmentation by revenue 2014
22.2.4 Business segmentation by revenue 2013 and 2014
22.2.5 Geographical segmentation by revenue 2014
22.2.6 Business strategy
22.2.7 Recent developments
22.2.8 SWOT analysis
22.3 UCB
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Product Segmentation by Revenue 2013
22.3.4 Product Segmentation by Revenue 2012 and 2013
22.3.5 Geographical Segmentation by Revenue 2013
22.3.6 Business Strategy
22.3.7 Recent Developments
22.3.8 SWOT Analysis
22.4 XenoPort
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Strategy
22.4.4 SWOT Analysis
23. Other Reports in this Series